Retrovirus-mediated gene transfer of receptor activator of nuclear factor-κB-Fc prevents bone loss in ovariectomized mice

Stem Cells

Volumn 24, Issue 7, 2006, Pages 1798-1805

  Kim, Dohee ^a   Sun, Wook Cho ^a   Sun, Ju Her ^a   Jae, Yun Yang ^a   Sang, Wan Kim ^a   Seong, Yeon Kim ^a   Chan, Soo Shin ^a  

^a Seoul National University   (South Korea)

Author keywords

Gene therapy; Mesenchymal stem cell; Osteoporosis; Ovariectomy; Receptor activator of nuclear factor B; Receptor activator of nuclear factor B Fc

Indexed keywords

GREEN FLUORESCENT PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATE BUFFERED SALINE; CARRIER PROTEIN; GFP10 PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MEMBRANE PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT PROTEIN; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE MARROW BIOPSY; BRAIN BIOPSY; CELL BASED GENE THERAPY; CELL LYSATE; CONTROLLED STUDY; DNA DETERMINATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR; GENE TRANSFER; HEART MUSCLE BIOPSY; LIVER BIOPSY; LUNG BIOPSY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RETROVIRUS; WESTERN BLOTTING; ANIMAL; ANIMAL MODEL; C57BL MOUSE; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; METABOLISM; STEM CELL TRANSPLANTATION;

ANIMALIA;

ANIMALS; BONE RESORPTION; CARRIER PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; IMMUNOGLOBULIN FC FRAGMENTS; MEMBRANE GLYCOPROTEINS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; OVARIECTOMY; POLYMERASE CHAIN REACTION; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT PROTEINS; RETROVIRIDAE; STEM CELL TRANSPLANTATION; TRANSFECTION;

EID: 33749076721     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2005-0480     Document Type: Article

References (40)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
2. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-74.
3. Bianco P, Riminucci M, Gronthos S et al. Bone marrow stromal stem cells: Nature, biology, and potential applications. STEM CELLS 2001;19:180-192.
4. Bartholomew A, Patil S, Mackay A et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001;12:1527-1541.
5. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-253.
6. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
7. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545.
8. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
9. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
10. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
11. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
12. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003;15:280-287.
13. Honore P, Luger NM, Sabino MA et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-528.
14. Bekker PJ, Holloway D, Nakanishi A et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-360.
15. Body JJ, Greipp P, Coleman RE et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97:887-892.
16. Sordillo EM. Pearse RN RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-812.
17. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001;98:11581-11586.
18. Bolon B, Carter C, Daris M et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther 2001;3:197-205.
19. Bailey EC, Milenkovic L, Scott MP et al. Several PATCHED1 missense mutations display activity in patched1-deficient fibroblasts. J Biol Chem 2002;277:33632-33640.
20. Jeon MJ, Kim JA, Kwon SH et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003;278:23270-23277.
21. Bellino FL. Nonprimate animal models of menopause: Workshop report. Menopause 2000;7:14-24.
22. Pereira RF, O'Hara MD, Laptev AV et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A 1998;95:1142-1147.
23. Azizi SA, Stokes D, Augelli BJ et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci U S A 1998;95:3908-3913.
24. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci U S A 2003;100(suppl):11917-11923.
25. Schwarz EJ, Alexander GM, Prockop DJ et al. Multipotential marrow stromal cells transduced to produce L-DOPA: Engraftment in a rat model of Parkinson disease. Hum Gene Ther 1999;10:2539-2549.
26. Hofstetter CP, Schwarz EJ, Hess D et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci U S A 2002;99:2199-2204.
27. Li Y, Chen J, Chen XG et al. Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology 2002;59:514-523.
28. Jin HK, Carter JE, Huntley GW et al. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002;109:1183-1191.
29. Toma C, Pittenger MF, Cahill KS et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98.
30. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003;100:8407-8411.
31. Krebsbach PH, Zhang K, Malik AK et al. Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: Human factor IX model. J Gene Med 2003;5:11-17.
32. Ding LM, Saylors R, Munshi NC. The stromal cell as a vehicle for ex vivo gene transfer. Blood 1997;89:446-456.
33. Chuah MK, Van Damme A, Zwinnen H et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000;11:729-738.
34. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-668.
35. Balsam LB, Wagers AJ, Christensen JL et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428:668-673.
36. Lazarus HM, Haynesworth SE, Gerson SL et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 1995;16:557-564.
37. Stewart FM, Crittenden RB, Lowry PA et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood 1993;81:2566-2571.
38. Bienzle D, Abrams-Ogg AC, Kruth SA et al. Gene transfer into hematopoietic stem cells: Long-term maintenance of in vitro activated progenitors without marrow ablation. Proc Natl Acad Sci U S A 1994;91:350-354.
39. Dickson GR, Luczak M, Wlodarski KH. The limitation of DEXA analysis for bone mass determination in mice. Folia Biol (Krakow) 2004;52:125-129.
40. Holdsworth DW, Thornton MM, Drost D et al. Rapid small-animal dual-energy X-ray absorptiometry using digital radiography. J Bone Miner Res 2000;15:2451-2457.